Related Experiment Video

Updated: Oct 19, 2025

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.5K

Histone Methylation Related Therapeutic Challenge in Cardiovascular Diseases

Yang Yang1, Ying Luan2, Rui-Xia Yuan1

  • 1Department of Translational Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Frontiers in Cardiovascular Medicine
|September 27, 2021
PubMed

Insights

Cardiovascular diseases (CVDs) involve vascular inflammation and cell death. Histone methylation, regulated by specific enzymes, plays a key role in CVD progression and offers potential therapeutic targets.

Area of Science:

  • Cardiovascular Science
  • Epigenetics
  • Molecular Biology

Background:

  • Cardiovascular diseases (CVDs) are a growing epidemic, driven by prevalent risk factors and complex pathophysiology.
  • CVD pathogenesis involves vascular inflammation, cell death, and dysregulated inflammatory responses.
  • Epigenetic alterations, particularly histone modifications, are crucial for cardiovascular homeostasis and disease development.

Purpose of the Study:

  • To review the role of histone methylation in cardiovascular system development and homeostasis.
  • To elucidate the impact of histone methyltransferases and demethylases on CVD pathogenesis.
  • To explore therapeutic strategies targeting histone methylation in CVDs.

Main Methods:

  • Literature review of studies on histone methylation in cardiovascular disease.
  • Analysis of enzymes (histone methyltransferases and demethylases) involved in cardiovascular histone methylation.
  • Examination of key proteins and cellular pathways regulated by histone methylation in CVDs.

Main Results:

  • Histone methylation is a critical, reversible epigenetic mechanism in cardiovascular health and disease.
  • Aberrant histone methylation by specific enzymes contributes to the progression of CVDs.
  • Histone methylation influences cardiomyocyte function and cellular pathways implicated in CVDs.

Conclusions:

  • Histone methylation is a significant factor in cardiovascular disease development and progression.
  • Targeting histone methylation and demethylation enzymes presents a promising therapeutic avenue for CVDs.
  • Further research into histone methylation inhibitors could lead to novel CVD treatments.

Keywords:
cardiovascular diseasesdemethylasesdemethylationhistone-methylationmethyltransferases

More Related Videos

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy07:02

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy

Published on: December 16, 2021

1.6K
Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

1.8K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
67
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
66
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
94
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
576
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
265